Publications
August 6, 2023
Interview: Applying multi-omics to novel target discovery in immuno-oncology
Ophir Eran and Turpaz Yaron. Immuno-Oncology Insights 2023; 4(6), 249–255
June 5, 2023
Poster: The combination of COM701 + BMS-986207 + nivolumab demonstrates preliminary antitumor activity in patients with recurrent, metastatic MSS endometrial cancer. NCT04570839
Rasco Drew. W et al, ASCO annual meeting, June 2-6, 2023
May 25, 2023
Abstract: The combination of COM701 + BMS-986207 + nivolumab demonstrates preliminary antitumor activity in patients with recurrent, metastatic MSS endometrial cancer. NCT04570839
Rasco Drew. W et al, ASCO annual meeting, June 2-6, 2023
May 5, 2023
Presentation: Unleashing natural IL18 activity using an anti-IL18BP blocker antibody induces potent immune stimulation and anti-tumor activity
Eran Ophir, CIMT annual meeting, May 5, 2023
May 4, 2023
Poster: Unleashing natural IL18 activity using an anti-IL18BP blocker antibody induces potent immune stimulation and anti-tumor activity
Assaf Menachem et al, CIMT annual meeting, May 4, 2023
April 26, 2023
Abstract: Unleashing natural IL18 activity using an anti-IL18BP blocker antibody induces potent immune stimulation and anti-tumor activity
Assaf Menachem et al, CIMT annual meeting, May 3-5, 2023
April 18, 2023
Poster: Gene Model Correction for PVRIG and TIGIT Single Cell Sequencing Data Enables Accurate Detection and Study of their Functional Relevance
Sergey Nemzer et al, AACR annual meeting, April 14-19, 2023
March 15, 2023
Abstract: Gene model correction for PVRIG and TIGIT in single cell sequencing data enables accurate detection and study of its functional relevance
Sergey Nemzer et al, AACR annual meeting, April 14-19, 2023
December 8, 2022
Presentation: Unlocking the potential of PVRIG & TIGIT pathways to deliver the next transformational cancer immunotherapy drugs
Eran Ophir, SVP Research & Drug Discovery, Compugen, TIGIT Axis Therapies Summit, December 8, 2022
December 8, 2022
Presentation Video: Unlocking the potential of PVRIG & TIGIT pathways to deliver the next transformational cancer immunotherapy drugs
Eran Ophir, SVP Research & Drug Discovery, Compugen, TIGIT Axis Therapies Summit, December 8, 2022
